COMPASS Pathways plc (NASDAQ:CMPS – Free Report) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for COMPASS Pathways in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will earn ($2.05) per share for the year. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share.
A number of other equities analysts also recently issued reports on the company. Maxim Group lowered their price target on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. HC Wainwright decreased their price target on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $33.60.
COMPASS Pathways Stock Up 2.5 %
CMPS stock opened at $3.73 on Wednesday. COMPASS Pathways has a one year low of $3.16 and a one year high of $12.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The firm has a market cap of $255.21 million, a PE ratio of -1.70 and a beta of 2.27. The firm’s fifty day moving average is $4.22 and its 200 day moving average is $5.81.
COMPASS Pathways (NASDAQ:CMPS – Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.04. During the same period last year, the business earned ($0.67) EPS.
Institutional Trading of COMPASS Pathways
Several large investors have recently bought and sold shares of the business. Flagship Harbor Advisors LLC acquired a new position in shares of COMPASS Pathways during the 4th quarter worth approximately $43,000. Franklin Resources Inc. boosted its stake in COMPASS Pathways by 4.4% during the third quarter. Franklin Resources Inc. now owns 295,785 shares of the company’s stock worth $1,810,000 after buying an additional 12,599 shares during the last quarter. Green Alpha Advisors LLC purchased a new stake in COMPASS Pathways in the 3rd quarter valued at $99,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of COMPASS Pathways in the 3rd quarter worth $131,000. Finally, Geode Capital Management LLC raised its holdings in shares of COMPASS Pathways by 160.3% during the 3rd quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock worth $266,000 after acquiring an additional 25,970 shares during the period. Hedge funds and other institutional investors own 46.19% of the company’s stock.
COMPASS Pathways Company Profile
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Recommended Stories
- Five stocks we like better than COMPASS Pathways
- What Does a Stock Split Mean?
- Oracle Announces Game-Changing News for the AI Industry
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- Consumer Staples Stocks, Explained
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.